Prashi Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Prashi Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $2.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Prashi Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $2.9M Trade | TransData Nexus

Prashi Pharma Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $2.9M Total Trade · DGFT Verified

Prashi Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.9M across 5 products in 4 therapeutic categories. Based on 153 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Tetracycline ($1.5M), Griseofulvin ($720.8K), Mebendazole ($398.2K).

Prashi Pharma Private Limited — Export Portfolio & Destination Treemap

Prashi Pharma Private Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Prashi Pharma Private Limited? — Company Overview & Market Position

Prashi Pharma Private Limited, established on December 23, 1998, is a privately held pharmaceutical company based in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24234MH1998PTC117590. As of the latest available data, Prashi Pharma has an authorized capital of ₹10 million and a paid-up capital of ₹9.9 million.

The company's registered office is located at 503, 5th Floor, Surya House, Shree Golvalkar Guruji Marg, Road No. 7, Near Vidyavihar Station, Vidyavihar East, Mumbai, Maharashtra, 400077, India. Prashi Pharma specializes in the manufacturing of pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has a significant production capacity, with the ability to manufacture approximately 200 million tablets, 20 million capsules, and 1 million bottles of syrups per month.

What Does Prashi Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Tetracycline$1.5M 2

Product Portfolio — Top 5 by Export Value

Prashi Pharma Private Limited exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Tetracycline	Antibiotics	$1.5M	63	8.7%	3
2	Griseofulvin	Advanced Antifungals	$720.8K	31	2.0%	7
3	Mebendazole	Antimalarial & Antiparasitic	$398.2K	32	2.9%	5
4	Levamisole	Antimalarial & Antiparasitic	$163.3K	15	6.1%	5
5	Norfloxacin	Advanced Antibiotics	$137.4K	12	1.7%	15

Prashi Pharma Private Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $2.9M. The top category is Antibiotics (50.9% of portfolio), followed by Advanced Antifungals (24.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Prashi Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Prashi Pharma operates a manufacturing facility located in Shirgaon, Palghar, Maharashtra. This plant is equipped with high-capacity production lines capable of producing 200 million tablets, 20 million capsules, and 1 million bottles of syrups monthly. The facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is in the process of obtaining WHO Good Manufacturing Practice (GMP) approval for this facility.

3Key Leadership

The leadership team at Prashi Pharma Private Limited includes:

Mr. Sunil Desai: Director since October 9, 2010.
Ms. Heena Desai Sunil: Director since October 9, 2010.
Mr. Manthan Sunil Desai: Director since June 20, 2013.

These individuals play pivotal roles in the strategic direction and operational management of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Prashi Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Prashi Pharma Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports pharmaceutical products to various countries, with a significant focus on African nations such as Nigeria, Sierra Leone, Democratic Republic of Congo, Angola, Mali, and the Republic of Guinea. While specific regulatory approvals in these markets are not detailed in the available sources, the company's export activities suggest compliance with international standards.

2Emerging Markets

Prashi Pharma has a notable presence in emerging markets, particularly in Africa. The company exports pharmaceutical products to countries including Nigeria, Sierra Leone, Democratic Republic of Congo, Angola, Mali, and the Republic of Guinea. The company's products have received approval from the African FDA, and it is in the process of obtaining WHO GMP approval, which will further facilitate access to these and other emerging markets.

3Geographic Strategy

Prashi Pharma's geographic strategy demonstrates a strong focus on the African continent, with exports to multiple countries in the region. This concentration indicates a strategic emphasis on emerging markets, potentially reducing exposure to risks associated with overreliance on a single region. The company's efforts to obtain WHO GMP approval suggest a commitment to meeting international standards, which may enhance its competitiveness in these markets.

Prashi Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Prashi Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not available in the provided sources. The company's export activities to regulated markets imply adherence to international standards, but explicit FDA approvals are not documented.

2WHO & EU GMP

Prashi Pharma is in the process of obtaining WHO GMP approval for its manufacturing facility in Shirgaon, Palghar, Maharashtra. This certification is crucial for accessing international markets and ensuring product quality. Specific details regarding EU GMP certification are not available in the provided sources.

3CDSCO & Indian Regulatory

Prashi Pharma holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Shirgaon, Palghar, Maharashtra, is operational and capable of producing a significant volume of pharmaceutical formulations. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not available in the provided sources.

Prashi Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Prashi Pharma operates in a competitive pharmaceutical industry, exporting products to various countries, including those in Africa. While specific competitors are not identified in the available sources, the company's focus on emerging markets and its efforts to obtain WHO GMP approval suggest a strategy aimed at differentiating itself through quality and compliance.

2Key Differentiators

Prashi Pharma's key differentiators include its significant manufacturing capacity, with the ability to produce 200 million tablets, 20 million capsules, and 1 million bottles of syrups per month. The company's focus on obtaining WHO GMP approval demonstrates a commitment to meeting international standards, which is crucial for accessing regulated markets.

3Strategic Position

Prashi Pharma's current strategic direction appears to focus on expanding its presence in emerging markets, particularly in Africa, by exporting pharmaceutical products and seeking international certifications such as WHO GMP. The company's significant manufacturing capacity supports this strategy, enabling it to meet the demands of these markets.

Buyer Due Diligence Brief — Evaluating Prashi Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Prashi Pharma has a track record of exporting pharmaceutical products to various countries, including Nigeria, Sierra Leone, Democratic Republic of Congo, Angola, Mali, and the Republic of Guinea. The company's significant manufacturing capacity and efforts to obtain WHO GMP approval indicate reliability and a commitment to quality.

2Certifications to Verify

Importers should verify the following certifications when considering Prashi Pharma as a supplier:

WHO GMP Certification: To ensure compliance with international manufacturing standards.

EU GMP Certification: If exporting to European markets, to meet regulatory requirements.

FDA Registration: For exports to the United States, to confirm compliance with FDA regulations.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from the supplier.

Frequently Asked Questions — Prashi Pharma Private Limited

How many pharmaceutical products does Prashi Pharma Private Limited export from India?

Prashi Pharma Private Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Tetracycline ($1.5M), Griseofulvin ($720.8K), Mebendazole ($398.2K), Levamisole ($163.3K), Norfloxacin ($137.4K). Total export value is $2.9M.

What is Prashi Pharma Private Limited's total pharmaceutical export value?

Prashi Pharma Private Limited's total pharmaceutical export value is $2.9M, based on 153 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Prashi Pharma Private Limited cover?

Prashi Pharma Private Limited exports across 4 therapeutic categories. The largest are Antibiotics (50.9%, 1 products), Advanced Antifungals (24.9%, 1 products), Antimalarial & Antiparasitic (19.4%, 2 products).

Get Full Prashi Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.